They found that not only was RA disease activity significantly improved, but the Krebs von den Lungen-6 (KL-6) level, which is associated with ongoing lung inflammation and active fibrosis, was also significantly reduced at 2 and 6 months after TCZ administration. The gene discussed is MUC1; the disease is rheumatoid arthritis.